Medicinal Products Receiving Expedited Approval in Europe May not Provide Intended Clinical Benefit (IMAGE)

PLOS

Medicinal Products Receiving Expedited Approval in Europe May not Provide Intended Clinical Benefit

Caption

The majority of marketing authorizations granted through two expedited assessment pathways in Europe are based on non-validated surrogate endpoints rather than clinical outcomes, according to a study published September 10 in the open-access journal PLOS Medicine by Patricia McGettigan of Queen Mary University of London, and colleagues.

Credit

DarkoStojanovic, Pixabay

Usage Restrictions

CC0 - Public domain, no usage restrictions

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.